SCHEMBL6998916

SCHEMBL6998916

C=CCOC(=O)Nc1cc(C=O)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SNCA P37840 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
EGFR P00533 2/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6999550 0.81 MEN1 (0.46) MEN1KMT2ACSNK2A2CSNK2A1CHRNB2
SCHEMBL2553202 0.79 POLB (0.52) MEN1KMT2AHSD17B10ALDH1A1ATM
SCHEMBL19035598 0.77 CHRNB2 (0.61) MEN1KMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL23009285 0.75 MEN1 (0.48) MEN1KMT2AKDM4EHSD17B10MAPK1
SCHEMBL1258539 0.75 ATR (0.47) JAK2JAK1TYK2
SCHEMBL2555419 0.75 EGFR (0.42) MEN1KMT2AEGFRALDH1A1
SCHEMBL5258921 0.74 MEN1 (0.49) MEN1KMT2ASNCACSNK2A2CSNK2A1
SCHEMBL7365972 0.73 L3MBTL1 (0.52) L3MBTL1JAK2JAK1TYK2PIK3C3
SCHEMBL29951814 0.73 L3MBTL1 (0.52) L3MBTL1JAK2JAK1TYK2PIK3C3
SCHEMBL18266478 0.73 JAK2 (0.50) MEN1KMT2AKDM4EHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531466-B2 E.g., a 1-aza-10-(1-hydroxyethyl-11-oxo-4-(het-methylene)-tricyclo(7.2 .0.0(3,8))undec-2-ene-2-carboxylate; good activity against grampositive bacteria such as methicillin-resistant Staphylococcus aureus and epidermidis GLAXOSMITHKLINE SPA (IT) 2003-03-11 US disclosed
EP-0937078-B1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXOSMITHKLINE SPA (IT) 2003-02-12 EP disclosed
US-20010047094-A1 Tricyclic carbapenem compounds GLAXO WELLCOME SPA 2001-11-29 US disclosed
EP-0937078-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.p.A. (IT) 1999-08-25 EP disclosed
WO-1998021210-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.P.A. (IT) 1998-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047094-A1 Tricyclic carbapenem compounds OXA1L, GNE, MGAM MEN1 2910/4885KMT2A 1665/4885SNCA 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.